XENE Financials: Xenon Pharmaceuticals Inc AI Analysis



Financials

XENE Financial

Xenon Pharmaceuticals Inc

$56.44

0.78%

$0.43

At close: May 08, 16:00:00 GMT-4

$56.44

Post-market: May 08, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$56

Open

$56.13

Day's Range

$55.73 - $57.47

52 week range

$28.19 - $63.95

Volume

886.5K

Avg.Volume

1.2M

Dividend yield

EPS (TTM)

-4.36

Market Cap

$5.2B

What is XENE?

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 358 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

Features

Markets

News

Income

Balance sheet

Cash flow

Annual

Quarterly

XENE Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	7	0	0	0	7	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	79	22	19	19	19	18
Research & Development	300	87	77	74	61	59
Operating Expenses	380	109	96	94	80	77
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-344	-104	-90	-85	-64	-69
Income Tax Expense	1	0	0	0	0	-3
Net Income	-345	-105	-90	-84	-65	-65
Net Income Growth	47%	62%	45%	47%	38%	48%
Shares Outstanding (Diluted)	80.12	80.12	79.24	78.95	78.68	78.38
Shares Change (YoY)	2%	2%	2%	2%	1%	12%
EPS (Diluted)	-4.31	-1.31	-1.14	-1.07	-0.82	-0.83
EPS Growth	43%	56.99%	42%	44%	34%	31%
Free Cash Flow	-279	-81	-72	-64	-61	-55
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-5,328.57%	0%	0%	0%	-1,028.57%	0%
Profit Margin	-4,928.57%	0%	0%	0%	-928.57%	0%
Free Cash Flow Margin	-3,985.71%	0%	0%	0%	-871.42%	0%
EBITDA	-371	-109	-96	-94	-72	-77
EBITDA Margin	-5,300%	0%	0%	0%	-1,028.57%	0%
D&A For EBITDA	2	0	0	0	0	0
EBIT	-373	-109	-96	-94	-72	-77
EBIT Margin	-5,328.57%	0%	0%	0%	-1,028.57%	0%
Effective Tax Rate	-0.29%	0%	0%	0%	0%	4.34%

Follow-Up Questions

What are Xenon Pharmaceuticals Inc's key financial statements?



According to the latest financial statement (Form-10K), Xenon Pharmaceuticals Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for XENE?



Xenon Pharmaceuticals Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Xenon Pharmaceuticals Inc's revenue broken down by segment or geography?



Currently Xenon Pharmaceuticals Inc data is not available.

Is Xenon Pharmaceuticals Inc profitable?



no, according to the latest financial statements, Xenon Pharmaceuticals Inc has a net loss of $0

Does Xenon Pharmaceuticals Inc have any liabilities?



no, Xenon Pharmaceuticals Inc has liability of 0

How many outstanding shares for Xenon Pharmaceuticals Inc?



Xenon Pharmaceuticals Inc has a total outstanding shares of 0

Xenon Pharmaceuticals Inc (XENE) Financial

XENE Stock Price Chart